Ozempic – pro
Semaglitide is a diabetes drug, and a side effect of it is weight loss, similar to other drugs in its class, but with a greater effect. It si not FDA-approved for weight loss for obesity, overweight or for cosmetic weight loss. Semaglutide treatment in a cohort study of adults with overweight or obesity, or for pre-diabetes in a regular clinical setting was associated with weight loss similar to that seen in randomized clinical trials for diabetes, which suggests its applicability for treating patients with overweight or obesity.
There is not sufficient literature at this point to securely understand the balance of harm over benefit from long term studies and its use fo obese and especially for non-obese patients is not medically necessary.
Lexicomp. Semaglutide: drug information. In: Post TW, ed. UpToDate. Waltham (MA): UpToDate; 2018: www.uptodate.com.
Wissam Ghusn et al, Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022;5(9):e2231982.
Ozempic Prescribing Information 2023